NLV-III
OrganizationRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
General Partner
|
Management contribution |
6
|
1 | |
|
organization
New Leaf
|
Management firm to fund |
5
|
1 | |
|
organization
Biopharma
|
Financial |
5
|
1 | |
|
organization
Pearl Therapeutics
|
Financial |
5
|
1 | |
|
person
Fund Managers
|
Management |
5
|
1 | |
|
organization
New Leaf
|
Management |
5
|
1 | |
|
person
NLV-II
|
Successor fund |
5
|
1 | |
|
organization
New Leaf
|
Management ownership |
5
|
1 | |
|
organization
New Leaf
|
Fund |
5
|
1 |
HOUSE_OVERSIGHT_024055.jpg
This document appears to be a page from an investment memorandum for 'NLV-III' (New Leaf Ventures III). It outlines the 'New Leaf' team's due diligence process, risk assessment factors (such as IP strength and regulatory risks), and team-oriented management philosophy. It also details the intended portfolio composition, targeting 24-28 companies with a specific asset allocation focused heavily on biopharmaceuticals (50-60%).
HOUSE_OVERSIGHT_024053.jpg
This document is page 42 of a confidential investment strategy memorandum for NLV-III (New Leaf Ventures III). It details the strategy for investing in 'Biological Research Tools & Infrastructure,' highlighting the benefits of lower regulatory risks compared to biopharma and aiming for companies near the commercial stage. The document notes that up to 15% of the fund will be allocated to this sector and medical devices, citing 'Advanced Cellular Diagnostics' from the previous NLV-II fund as a successful example.
HOUSE_OVERSIGHT_024052.jpg
This document appears to be page 41 of a confidential investment memorandum for 'New Leaf,' specifically regarding their third fund, NLV-III. It outlines the 'Medical Devices Investment Strategy,' emphasizing a shift toward later-stage opportunities due to regulatory headwinds in the U.S. and E.U. The document cites specific portfolio successes like Neuronetics, CardioKinetix, and the acquisition of Interlace Medical by Hologix to demonstrate the team's track record.
HOUSE_OVERSIGHT_024050.jpg
This document is page 39 of a confidential investment memorandum or fund report stamped by House Oversight. It details specific healthcare investment themes including Care Coordination, Clinical Error Reduction, and Analytics/Data-Driven Personalization, highlighting portfolio companies such as TigerText, ePocrates, iRhythm Technologies, and Treato. The document notes the financial success of ePocrates (acquired for $293 million) and attributes several companies to a fund designated as 'NLV-II'.
HOUSE_OVERSIGHT_024049.jpg
This document appears to be page 38 of a confidential investment memorandum for New Leaf Ventures (specifically fund NLV-III). It outlines the firm's 'Information Convergence' investment strategy, focusing on healthcare technology solutions that address inefficiencies and rising costs in the U.S. healthcare system. It cites 'AwarePoint' (from fund NLV-II) as a case study. The document bears a House Oversight Committee Bates stamp, suggesting it was part of a document production for a congressional investigation, likely related to the financial networks surrounding Jeffrey Epstein, though Epstein is not explicitly named on this specific page.
HOUSE_OVERSIGHT_024046.jpg
This document appears to be page 35 of a confidential investment memorandum for a fund named NLV-III (likely New Leaf Venture Partners). It outlines the fund's track record with previous investments (NLV-II) in companies like Array, Acadia, and Intercept Pharmaceuticals, highlighting successful exit multiples. The text details the investment thesis for NLV-III, focusing on targeted biopharmaceutical therapies and biomarker-guided programs that benefit patients, physicians, payers, and pharmaceutical companies. The document bears a House Oversight Committee stamp.
HOUSE_OVERSIGHT_024043.jpg
This document is page 32 of a confidential investment memorandum (Control Number 257) produced for the House Oversight Committee. It outlines the investment strategy for 'NLV-III' (New Leaf Ventures III), focusing on biopharmaceutical companies with novel products or platforms. The text highlights past successes of the fund managers, listing exit multiples for companies such as Array BioPharma, Pearl Therapeutics, and Epizyme.
HOUSE_OVERSIGHT_024042.jpg
This document is page 31 of a confidential investment strategy memorandum for New Leaf Venture Partners' third fund (NLV-III). It outlines the fund's strategy to invest in 24-28 companies, primarily in the U.S., with a 50-60% allocation focus on Biopharmaceuticals, alongside Information Convergence and Medical Devices. The document bears a House Oversight Bates stamp, indicating it was obtained as part of a congressional investigation, likely regarding financial connections.
HOUSE_OVERSIGHT_024040.jpg
This document is page 29 of a confidential investment report or prospectus, likely for a fund named NLV-III (New Leaf Ventures). It analyzes the contraction in the healthcare venture capital industry between 2007 and 2012, arguing that this creates favorable investment opportunities due to reduced competition. It also highlights the positive impact of the 2012 JOBS Act and a strong IPO market in 2013/2014 on biopharmaceutical companies.
HOUSE_OVERSIGHT_024035.jpg
This document appears to be page 24 of a confidential investment memorandum for a fund named 'NLV-III'. It outlines the 'Opportunity in the Healthcare Sector,' citing macro-economic factors such as aging populations, outpacing GDP growth, and emerging market expansion (BRICs) as justifications for investment in healthcare technology. The document bears a House Oversight Bates stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024032.jpg
This document is a confidential financial chart titled 'Returns by Fund' as of March 31, 2014, bearing a House Oversight stamp. It details the performance metrics (IRR, Multiples, Capital) for six funds: Growth II HCT, Sprout VII HCT, Sprout VIII HCT, Sprout IX HCT, NLV-I, and NLV-II. The chart compares these funds against public indices like the S&P 500 and Nasdaq, showing significant distributed capital totaling over $1 billion for the largest fund listed.
HOUSE_OVERSIGHT_024024.jpg
This document (page 13, Control Number 257) contains professional biographies for James Niedel and Liam Ratcliffe, executives at New Leaf Venture Partners. It details their educational backgrounds, board memberships, and extensive history in the pharmaceutical industry (GSK and Pfizer respectively), including specific successful drug developments and corporate acquisitions. The document is marked confidential and bears a House Oversight file stamp.
HOUSE_OVERSIGHT_024019.jpg
This document appears to be page 8 of a confidential investment memorandum for a fund identified as NLV-III (likely New Leaf Ventures III). It outlines the fund's investment strategy regarding Healthcare Information Technology (HIT), Medical Devices, and Biological Research Tools. The text discusses the impact of the HITECH Act and government funding on the market, arguing that regulatory challenges in medical devices will lead the fund to focus on later-stage opportunities, while highlighting the potential of smaller companies in HIT and research tools. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024018.jpg
This document appears to be a page from a confidential investment prospectus for a fund named 'NLV-III' (likely New Leaf Ventures). It outlines the investment strategy, focusing on biopharmaceutical trends such as FDA 'breakthrough therapy' designations and 'information convergence' in healthcare to reduce costs. The document cites a 2013 editorial by FDA Director Janet Woodcock and notes the evolving commercial models of large pharmaceutical companies.
HOUSE_OVERSIGHT_024017.jpg
This document is page 6 of a confidential investment memorandum for New Leaf Ventures III (NLV-III). It outlines the fund's investment strategy, which focuses primarily on the Biopharmaceutical and Information Convergence sectors in the U.S., with a specific emphasis on targeted therapeutics and molecular mechanisms. The document highlights favorable market conditions and a cooperative regulatory environment with the FDA as key drivers for the fund's potential success.
HOUSE_OVERSIGHT_024016.jpg
This document appears to be page 5 of a confidential investment memorandum for a fund named 'NLV-III' (likely New Leaf Ventures III). It outlines the investment thesis, citing a favorable regulatory environment due to increased FDA approvals and the FDASIA act of 2012, as well as favorable capital market dynamics caused by a contraction in venture capital fundraising which reduces competition for deals. The document bears a House Oversight Committee stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024010.jpg
This document appears to be page 'vi' (roman numeral 6) of a larger financial or legal document, marked confidential with control number 257 and a House Oversight Bates stamp. It contains a specific legal disclaimer asserting that investment interests in 'NLV-III' are not endorsed, promoted, or sold by Credit Suisse, despite the mention of Credit Suisse trademarks.
HOUSE_OVERSIGHT_024009.jpg
This page contains legal disclaimers for a confidential investment memorandum, likely regarding New Leaf Ventures funds (I, II, and III). It includes standard warnings regarding forward-looking statements, tax liabilities (IRS Circular 230), and investment risks. The document explicitly states that the information is current as of March 31, 2014, and clarifies that Credit Suisse has no affiliation with the funds mentioned and did not prepare the memorandum.
HOUSE_OVERSIGHT_024005.jpg
This document is the 'Statement of Conditions' page (page 'i') from a Confidential Private Placement Memorandum for 'New Leaf Ventures III, L.P.' (NLV-III), a Delaware Limited Partnership. It contains standard legal disclaimers regarding the SEC, the Securities Act of 1933, and the Investment Company Act of 1940, warning investors that the fund is unregistered and high-risk. The document bears a 'CONTROL NUMBER 257 - CONFIDENTIAL' and a 'HOUSE_OVERSIGHT_024005' stamp, indicating it was part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024110.jpg
This document is a glossary or appendix (page 99) from a confidential House Oversight financial report defining accounting terms H through N. It details calculation methods for financial metrics such as Paid-in Capital, Realized Cost/Value, and Unrealized Value, specifically referencing funds 'NLV-I' and 'NLV-II' and the role of the General Partner in determining fair value.
HOUSE_OVERSIGHT_024108.jpg
This document is Appendix 5 (Endnotes) of a confidential financial report dated as of March 31, 2014, obtained by the House Oversight Committee (Bates stamp HOUSE_OVERSIGHT_024108). It outlines the methodology for financial performance reporting for funds identified as NLV-I, NLV-II, and the Sprout Funds, distinguishing between 'gross' and 'net' performance and providing legal disclaimers regarding valuations and future results. The document defines the roles of generic 'Fund Managers' and the 'Sprout Group' in managing these investments.
HOUSE_OVERSIGHT_024074.jpg
This document appears to be page 63 of a confidential Private Placement Memorandum or Offering Memorandum describing risk factors for an investment fund. It details the lack of control Limited Partners have over management, reliance on the General Partner and Fund Managers, and potential conflicts of interest arising from the managers' involvement with other entities like 'Sprout Funds,' 'NLV-I,' and 'NLV-II.' The document bears a House Oversight control number, suggesting it was produced during a congressional investigation.
HOUSE_OVERSIGHT_024073.jpg
This document is page 62 of a confidential offering memorandum (likely a Private Placement Memorandum) for a fund identified as 'NLV-III'. It outlines significant risk factors for potential investors, including the illiquidity of investments, the lack of operating history for the newly formed Fund and General Partner, the lack of assurance regarding profits or distributions, and the highly competitive nature of venture capital investments. The document bears a House Oversight Committee stamp, indicating it is part of a congressional investigation.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity